Abstract 7354: ETS1 orchestrates a hybrid EMT program to drive metastasis and immune evasion in UASCC

Abstract Intratumoral transcriptional heterogeneity (ITH) is a defining feature of aggressive cancers, yet the mechanisms by which distinct ITH programs drive metastasis and immune escape in upper aerodigestive squamous cell carcinoma (UASCC) remain poorly understood. Using single-cell RNA sequencing of cancer cell lines and patient tumors, we identified a hybrid epithelial-mesenchymal transition (hEMT) program strongly associated with metastatic potential. We determined that the transcription factor ETS1 functions as a master regulator of this hEMT state, directly activating pro-invasive and pro-metastatic gene networks and promoting distant dissemination in vivo. Beyond its role in metastasis, ETS1 unexpectedly established an immune-cold microenvironment by transcriptionally inducing STAT1 and PD-L1 (CD274), leading to reduced T-cell infiltration and elevated immune checkpoint expression. Clinically, ETS1-high tumors were consistently linked to poor survival and diminished responses to immune checkpoint blockade across multiple independent cohorts. Through a focused drug screen, we found that ETS1-high cancers exhibit selective vulnerability to HSP90 inhibition (e.g., Alvespimycin), which reduces ETS1 expression via disruption of HIF1A-driven transcription. Together, these findings define ETS1 as a central driver of both metastatic progression and immune evasion in UASCC and nominate HSP90 inhibitors as a promising therapeutic strategy for ETS1-driven disease states. Citation Format: Chehyun Nam, Talia Wenger, Benjamin Ziman, Daniel Arnaudov, Thomas Tilton, Ethan Pan, Young Min Park, Uttam K. Sinha, De-Chen Lin1.. ETS1 orchestrates a hybrid EMT program to drive metastasis and immune evasion in UASCC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7354.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-7354
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 7354: ETS1 orchestrates a hybrid EMT program to drive metastasis and immune evasion in UASCC

Benjamin Ziman, Chehyun Nam, Talia A. Wenger, D Arnaudov et al.
Cancer Research
Cancer Immunotherapy and Biomarkers
article

Abstract 7354: ETS1 orchestrates a hybrid EMT program to drive metastasis and immune evasion in UASCC

Benjamin Ziman, Chehyun Nam, Talia A. Wenger, D Arnaudov, Thomas Tilton, De-Chen Lin1., Ethan Pan, Young Min Park
article en

Abstract

Abstract Intratumoral transcriptional heterogeneity (ITH) is a defining feature of aggressive cancers, yet the mechanisms by which distinct ITH programs drive metastasis and immune escape in upper aerodigestive squamous cell carcinoma (UASCC) remain poorly understood. Using single-cell RNA sequencing of cancer cell lines and patient tumors, we identified a hybrid epithelial-mesenchymal transition (hEMT) program strongly associated with metastatic potential. We determined that the transcription factor ETS1 functions as a master regulator of this hEMT state, directly activating pro-invasive and pro-metastatic gene networks and promoting distant dissemination in vivo. Beyond its role in metastasis, ETS1 unexpectedly established an immune-cold microenvironment by transcriptionally inducing STAT1 and PD-L1 (CD274), leading to reduced T-cell infiltration and elevated immune checkpoint expression. Clinically, ETS1-high tumors were consistently linked to poor survival and diminished responses to immune checkpoint blockade across multiple independent cohorts. Through a focused drug screen, we found that ETS1-high cancers exhibit selective vulnerability to HSP90 inhibition (e.g., Alvespimycin), which reduces ETS1 expression via disruption of HIF1A-driven transcription. Together, these findings define ETS1 as a central driver of both metastatic progression and immune evasion in UASCC and nominate HSP90 inhibitors as a promising therapeutic strategy for ETS1-driven disease states. Citation Format: Chehyun Nam, Talia Wenger, Benjamin Ziman, Daniel Arnaudov, Thomas Tilton, Ethan Pan, Young Min Park, Uttam K. Sinha, De-Chen Lin1.. ETS1 orchestrates a hybrid EMT program to drive metastasis and immune evasion in UASCC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7354.

Cancer ResearchVol. 86(7_Supplement)
University of Southern California (US), Yonsei University (KR), Keck Hospital of USC (US), Kaiser Permanente Walnut Creek Medical Center (US)
No poverty
Openalex Percentile: Top 18%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.